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Chimeric antigen receptors (CARs) are genetically engineered receptors that provide specific properties to an immune effector cell and 
these receptors gain the specificity of a monoclonal antibody targeted against specific tumor cells. T cells with engineered CARs acquire 
potent immunological properties and redirect the immune system in order to eliminate malignant cells. First-engineered T cells with 
chimeric molecule (CAR-T cells) were developed in 1989–1993 by Israeli immunologists Zelig Eshhar and Gideon Gross. The first clinical 
application of CAR-T cells was done in the University of Pennsylvania and Children’s Hospital in Philadelphia by the immunologist Carl 
June and hematologist David Porter to patients with chronic lymphocytic leukemia in 2011 and together with the pediatrician Stephan 
Grupp to patients with acute lymphoblastic leukemia (ALL) in 2012. The US Food and Drug Administration Agency (FDA) in 2017 and the 
European Medicines Agency (EMA) in 2018 have licensed two products of CAR-T cells: tisagenlecleucel for the use in children and young 
adults up to 25 years of age with B-cell ALL who do not respond to treatment or have relapsed two or more times and tisagenlecleucel 
and axicabtagene ciloleucel for the use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Current 
progress in CAR technology includes the use in other hematological malignancies, solid tumors, the use of dual CAR-T cells and chimeric 
antigen receptor natural killer cells (CAR-NK cells).
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Chimeric antigen receptor
Chimeric antigen receptors (CARs) are genetically engineered 
receptors that provide specific properties to an immune effector cell 
(e.g., lymphocyte T-cell). These receptors gain the specificity of a 
monoclonal antibody targeted against specific tumor cells. The coding 
sequence is transferred to the receptor by viral (retroviral and lentiviral) 
vectors. The term “chimeric” indicates different sources of composing 
parts of the receptor. T cells with engineered CARs acquire potent 
immunological properties and by redirecting the immune system in 
order to eliminate malignant cells act as a living drug, expanding in the 
patient and ensuring long-term antitumor memory [1, 2, 3].
CAR-T cells can be either autologous or allogenic. Autologous CAR-T 
cells are derived via leukapheresis from the blood of the patient. 
Allogenic CAR-T cells are derived from the blood of a healthy donor. 
CARs as recombinant receptors transferred in various T-cell subsets 
provide in a restricted manner specific antigen binding in a non-major 
histocompatibility complex (non-MHC) [3]. Theoretically, CAR-T cells 
can be engineered to target virtually any tumor-associated antigen and, 
in general, any other antigen, e.g., fungal antigen [4].
Four generations of CARs
First engineered T-cell with chimeric molecule was developed in 1989–
1993 by Israeli immunologists Zelig Eshhar and Gideon Gross in the 
Department of Chemical Immunology of Weizmann Institute of Science 
in Rehovot, Israel (Tab. I). These first-generation CARs were not yet 
clinically effective [5, 6, 7].
Over next thirty years, CARs were immunologically and technologically 
modernized and sophisticated as first, second, third, and currently fourth 
generation, depending on their composition. The second-generation CARs 
had improved antitumor activity of T cells: improved T-cell proliferation, 
resistance to apoptosis, cytokine secretion, and in vivo persistence. The 
third-generation CARs, in comparison with second-generation CARs, had 
improved effector functions and in vivo persistence [8, 9].
Fourth-generation CARs, the so-called TRUCKs (CAR redirected T 
cells that deliver a transgenic product to the targeted tumor tissue) 
or armored CARs, present further enhancement in antitumoral 
potency, cytokine activity, and costimulatory ligands and enzymes that 
can degrade the extracellular matrix in solid tumors [9, 10]. Further 
enhancement in the safety of CAR-T cell therapy can be obtained with 
the so-called smart T cells, which is under investigation [11, 12, 13].
Finally, new engineering modalities, based on the use of targeted 
nucleases like clustered regularly interspaced short palindromic 
repeats (CRISPR), may further enhance the efficacy and safety of 
CAR-T cells [14].
First clinical application
Clinical application of CAR-T cells became available through the 
dedicated team in the University of Pennsylvania and Children’s 
Hospital in Philadelphia. Carl June was the immunologist who led the 
development of CAR-T cell technology, striving with many difficulties. 
Together with David Porter and Stephan Grupp, he administered 
CAR-T cells to patients with chronic lymphocytic leukemia (CLL) in 
2011 [1] and ALL in 2012 [2].
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The real progress was achieved with the first therapy in child with 
ALL: a 7-year-old Emily Whitehead with relapsed and refractory 
ALL, who was recommended to hospice, became the first 
child to receive CART-19 in 2012. She experienced all severe 
complications of this therapy, but she was finally cured. As a 
result, her survival helped reenergize a line of research that was 
near the failure [15].
Current status
The US Food and Drug Administration Agency (FDA) and the 
European Medicines Agency (EMA)  have licensed two products 
of CAR-T cells: tisagenlecleucel for the use in children and young 
adults up to 25 years of age with B-cell ALL that does not respond to 
treatment or has relapsed two or more times, and tisagenlecleucel 
and axicabtagene ciloleucel for the use in adult patients with relapsed 
or refractory diffuse large B-cell lymphoma (DLBCL) (Tab. II). Several 
other products are at different stages of research and progress 
toward registration (Tab. III).
Further progress and worldwide distribution
Owing to emergence of relapse of ALL with cells that do not express 
CD19 in mechanisms of a phenomenon known as antigen escape, 
the Phase I study with the use of CAR-T cells with dual targeting of 
CD19/CD22 has demonstrated good efficacy, safety, and tolerability, 
thus opening possibility to trials studying bispecific targeting to 
circumvent CD19 down-regulation [17, 23, 24].
An option to increase the potential of CAR-T cells is its enhancement 
by combining CAR-T cells with a monoclonal antibody targeting the 
human programmed death receptor 1 (anti-PD1) performed so far in 
the prostate cancer model [25].
As of December 2019, there were 284 ongoing clinical trials (www.
clinicaltrials.gov) happening globally involving CAR-T cells, mostly in the 
USA (130) and China (124), most of them in hematological malignancies 
(ALL, non-Hodgkin lymphoma, multiple myeloma), targeting mostly 
CD19 and also CD20, CD22, and BCMA, almost exclusively CAR-T 
cells, but in 10 cases also CAR-NK [16] (majority in China). Currently, at 
least 24 countries use CAR-T cell technology in therapy [26].
Table I. History of development of CAR effector cells
Year Achievement
1989 Generation of effector T cells expressing chimeric T-cell receptor [5, 6]
1993 First-generation CAR-T cells, not clinically effective [7]
2002 First effective CAR-T cells against prostate cancer antigen in the laboratory
2003 Second-generation CARs: CD19-directed CAR-T cells can kill leukemia cells in mouse
2009 CD19 CAR-T cells used in relapsed/refractory leukemia
2011 CD19 CAR-T cells in patients with chronic lymphocytic leukemia [1]
2013 CD19 CAR-T cells in pediatric acute lymphoblastic leukemia [2]
2013 Science magazine announced cancer immunotherapy as “Breakthrough of the Year”
2014 Third-generation CAR-T cells: inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities [8]
2015 Fourth-generation CARs, the so-called TRUCKs (CAR redirected T cells that deliver a transgenic product to the targeted tumor tissue) or armored CARs, 
which produce other molecules built and being tested for ovarian cancer [10]
2015 Concept of CAR-NK  cells [16]
2017 Clustered regularly interspaced short palindromic repeats (CRISPR) used to optimize CAR placement in T cells [14]
2017 FDA approves CD19-CAR-T cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
2017 FDA  approves CD19-CAR-T cells for relapsed/refractory DLBCL in adults
2018 EMA approves CD19-CAR-T cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults and for relapsed/refractory DLBCL in adults
2019 Dual CD19/CD22 CAR-T cells in acute lymphoblastic leukemia in children and adults [17]
CAR – chimeric antigen receptor; CRISPR – clustered regularly interspaced short palindromic repeats; FDA – US Food and Drug Administration Agency; EMA – 
European Medicines Agency; DLBCL – diffuse large B-cell lymphoma.
Table II. Approval of CAR-T cell technology for clinical use
Date Authorities CAR-T cell Study Indications
August 30, 
2017




ELIANA, Maude et 
al. [18]
Children and young adults up to 25 years of age with 
B-cell ALL who do not respond to treatment or have 
relapsed two or more times
October 18, 
2017






Adult patients with relapsed or refractory DLBCL




JULIET, Schuster et 
al. [20]
Adult patients with relapsed or refractory DLBCL, 
high grade B-cell lymphoma, and DLBCL arising from 
follicular lymphoma




ELIANA, Maude et 
al. [18]
Children and young adults up to 25 years of age with 
B-cell ALL who do not respond to treatment or have 
relapsed two or more times






Adult patients with relapsed or refractory DLBCL
CAR – chimeric antigen receptor; ALL – acute lymphoblastic leukemia; DLBCL – diffuse large B-cell lymphoma.
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Table III. Advanced research in CAR-T cell application
CAR-T cell Study Indications Comments
Lisocabtagene maraleucel (Lisocel, 
Bristol-Myers Squibb/Celgene 
Company)
TRANSCEND NHL 001 trial, Abramson 
et al. [21]
Adult patients with relapsed or refrac-
tory (R/R) DLBCL after at least two 
prior therapies
Application to FDA (December 18, 
2019)
Idecabtagene Vicleucel (CT053, 
CARsgen Therapeutics)
KarMMa Multiple myeloma The FDA has given (September 5, 
2019) orphan drug status to CT053  
(anti-B-cell maturation antigen (an-
ti-BCMA)), an investigational chimeric 
antigen receptor T-cell therapy for the 
treatment of multiple myeloma
Anti-BCMA CAR-T cell bb2121 therapy 
(Bluebird Bio and Celgene)
CRB-401 trial, Raje et al. [22] Relapsed or refractory multiple 
myeloma
The product was granted break-
through therapy designation by 
the FDA in November 2017 and will 
thus receive expedited review by the 
agency. It has also been fast-tracked 
in Europe
Axicabtagene ciloleucel (Yescarta, 
Gilead-Kite)
ZUMA-3 (adult) and ZUMA-4 (pediat-
ric and adolescents 2–21 years)
1. Shah BD et al. ASCO 2019. Abstract 
7006
2. Lee DW et al. ESMO 2017. Abstract 
1008PD
ALL in children and adults Registration in progress
CAR – chimeric antigen receptor; NHL – non-Hodgkin lymphoma; DLBCL – diffuse large B-cell lymphoma; FDA – US Food and Drug Administration Agency; 
ALL – acute lymphoblastic leukemia.
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